[{"id":"6bf88660-ab14-45e2-bb64-b08b23bfb526","acronym":"","url":"https://clinicaltrials.gov/study/NCT04867928","created_at":"2021-04-30T11:55:13.741Z","updated_at":"2024-07-02T16:36:15.256Z","phase":"Phase 2","brief_title":"Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04867928","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" FLT3 • ABL1 • NPM1","pipe":" | ","alterations":" NPM1 mutation • FLT3-ITD mutation + NPM1 mutation","tags":["FLT3 • ABL1 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • FLT3-ITD mutation + NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2022-03-16"}]